LESSON 02
Diagnostics & Medical Devices
Medical Device Classification and the Regulatory Pathway
FDA classification is not a bureaucratic formality — it determines how much evidence you need, how long it takes, and how much it costs to reach the market.
13 min read
Every medical device sold in the United States must be classified by the FDA before it reaches the market, and that classification determines almost everything about the development program a company must run. The classification system has three tiers, labeled Class I, II, and III, based on the level of risk the device poses to patients. A Class I device like a tongue depressor carries minimal risk and requires only general controls — basic manufacturing and labeling standards. A Class III device like an implantable cardiac defibrillator carries the highest risk and requires the most rigorous evidence pathway. Most diagnostics and medical devices fall somewhere in between, in Class II, which is where the regulatory strategy becomes genuinely complex.
Class II devices reach the market through a process called 510(k) clearance. The legal standard for 510(k) is substantial equivalence — the applicant must demonstrate that their device is as safe and effective as a legally marketed predicate device. The predicate does not need to be identical; it needs to be similar in intended use and technological characteristics. Choosing the right predicate is one of the most consequential early decisions in a device regulatory strategy, because it defines the performance benchmarks the FDA will expect you to meet and the type of testing data you will need to generate. A predicate that was cleared with minimal clinical data creates a favorable precedent; a predicate that required extensive clinical studies signals what FDA expects from your submission.
Class III devices require Premarket Approval, or PMA, which is the most rigorous pathway available. PMA requires valid scientific evidence — typically data from well-controlled clinical investigations — demonstrating reasonable assurance of safety and effectiveness. PMA is appropriate for devices that support or sustain human life, present unreasonable risk of illness or injury, or are novel enough that substantial equivalence cannot be established. The process is expensive, time-consuming, and resource-intensive in ways that early-stage companies routinely underestimate. A PMA submission can cost tens of millions of dollars and take multiple years, and FDA has the authority to require additional studies after initial review.
For novel diagnostics where no predicate exists, a third pathway called De Novo classification is available. De Novo allows FDA to create a new regulatory classification for a device that is low to moderate risk but cannot claim substantial equivalence because it is genuinely new. A successful De Novo creates a new predicate that future entrants can reference in 510(k) submissions. For diagnostics companies developing genuinely novel tests, De Novo is often the most appropriate pathway — but it requires more data than a standard 510(k) and more time, because FDA must develop the regulatory framework for the category alongside evaluating the specific device.
Breakthrough Device Designation is an FDA program that provides more interactive review for devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases. Breakthrough designation does not guarantee faster approval — it guarantees more frequent communication with FDA during development. For diagnostics companies, this means earlier alignment on study design, analytical validation protocols, and acceptable performance criteria before investing in large clinical trials. The designation is valuable primarily as a risk-reduction tool, not a timeline guarantee.
Quality management systems, governed by FDA's Quality System Regulation — now aligned with ISO 13485 — are not a post-clearance formality. They must be in place before clinical studies begin, because any data collected before a compliant quality system is established may be rejected as part of a regulatory submission. Founders who treat quality as an end-stage activity rather than a foundation often discover late in development that their clinical study data is compromised, which requires either repeating studies or explaining deficiencies to FDA — neither of which is cheap or fast.
The regulatory pathway in Europe differs substantially from the United States. The EU Medical Device Regulation, or MDR, replaced the prior CE marking directives and introduced significantly more rigorous clinical evidence requirements for many device categories. MDR requires clinical data that demonstrates conformity with general safety and performance requirements, and for Class IIb and Class III devices, that data must include clinical investigations rather than literature reviews alone. Many companies that previously gained EU market access through the older, less demanding In Vitro Diagnostic Directive are now discovering that MDR requires studies they have not yet run.
Regulatory strategy is product strategy. The pathway you choose determines the clinical studies you run, the timeline you pitch to investors, and the price you can charge at launch.
This lesson is coming soon.
TERMS
Term of focus
510(k) Clearance
A premarket submission that demonstrates a device is substantially equivalent to a legally marketed predicate device in terms of intended use and technological characteristics. Clearance does not mean the device is approved — it means FDA has found it substantially equivalent to something already on the market. The choice of predicate and the performance benchmarks it implies are the most strategically important elements of a 510(k) strategy.
The most stringent FDA premarket review pathway, required for Class III devices that cannot demonstrate substantial equivalence and carry significant patient risk. PMA requires valid scientific evidence, typically including clinical investigation data, demonstrating reasonable assurance of safety and effectiveness. The PMA process typically costs tens of millions of dollars and takes several years from submission to decision.
A regulatory pathway for novel, low-to-moderate-risk devices that cannot reference a valid predicate for 510(k) clearance. A successful De Novo request results in FDA creating a new device classification and establishing special controls, and the cleared device becomes a predicate for future 510(k) submissions. De Novo is the appropriate pathway for diagnostics that are genuinely first-in-class rather than incrementally different from existing tests.
A legally marketed device to which a 510(k) applicant claims substantial equivalence. The predicate defines the performance benchmarks, technological characteristics, and intended use claims that FDA will use to evaluate the submission. Predicate selection is a strategic decision because it sets the evidentiary floor for the submission — a predicate cleared with limited data creates a favorable precedent, while a predicate that faced extensive scrutiny signals what FDA expects.
An FDA program that provides expedited interaction and review for devices intended to treat or diagnose life-threatening or irreversibly debilitating diseases that offer more effective alternatives to existing treatments. Breakthrough designation provides access to senior FDA staff for more frequent meetings and early alignment on study design and performance criteria. It reduces development risk by enabling earlier agency alignment, but does not accelerate the substantive review once a submission is filed.
A documented system of processes, procedures, and records that governs how a medical device is designed, manufactured, and supported throughout its lifecycle. FDA's Quality System Regulation and ISO 13485 define the requirements for medical device QMS. A compliant QMS must be established before clinical studies begin, because data generated outside a QMS environment may be rejected in a regulatory submission.
The European Union regulation that replaced the prior Medical Device Directive and In Vitro Diagnostic Directive, introducing significantly more rigorous clinical evidence and post-market surveillance requirements for medical devices sold in the EU. MDR requires clinical evidence demonstrating conformity with safety and performance requirements, and for higher-risk devices, this must include data from clinical investigations rather than literature reviews alone. Many companies that previously had EU market access under the older directives are discovering they need substantially more data to maintain it under MDR.
BEFORE YOUR NEXT MEETING
— What is the FDA classification for our device, and have we validated that classification with a regulatory consultant — not just inferred it from a product description?
— Which predicate device are we relying on for our 510(k), and what evidence did that predicate require? Have we confirmed FDA's current expectations match the predicate's clearance history?
— If we cannot establish substantial equivalence, have we modeled the De Novo pathway — including timeline, cost, and the additional data FDA would require to create a new classification?
— Is our quality management system in place and compliant with ISO 13485 before our clinical studies begin, or are we planning to build it concurrently with data collection?
— Have we assessed our EU MDR requirements separately from our FDA pathway, and do we understand whether the clinical data we are generating for FDA will satisfy MDR conformity requirements?
REALITY CHECK
SOURCES
LESSON 02 OF 04